ВSВ. А. Снежицкий (V. A. Snezhitskiy)

В. А. Снежицкий (V. A. Snezhitskiy)

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


В. А. Снежицкий (V. A. Snezhitskiy) has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Old enemy, new approach: highlighting a move to optimize survival in infarct-related cardiogenic shock. a narrative review

    by Viktor A. Snezhitskiy, Снежицкий Виктор Александрович, Naveen D.K.N. Direcksze, Direcksze Naveen D.K.N., Narendiran Yohanathan, Yohanathan Narendiran, M. Affri Ashroff Rumi, Rumi M. Affri Ashroff

    Cardiogenic shock is the most frequent type of shock observed in intensive care unit patients with an incidence rate of 3%–10%. In-hospital mortality remains very high, earlier it was estimated to be ranging from 30%–40%. The management of cardiogenic shock has been significantly improved over the past decade, but the mortality of patients with acute myocardial infarction and cardiogenic shock has shown no significant decline. Cardiogenic shock is a shock syndrome associated with end organ dysfunction due to systemic hypoperfusion caused by inadequacy of the heart in generating sufficient cardiac output. The latter may be caused by several underlying causes with the most common being acute myocardial infarction. This article illustrates a summary of the management of acute myocardial infarction related cardiogenic shock based on current guidelines. The keystone treatment of acute coronary syndrome and cardiogenic shock is culprit-lesion percutaneous coronary intervention. Restoration of end organ perfusion (hemodynamic maintenance), and the aspects of general support have the crucial value. Recent studies have shown that mechanical cardiac support such as Impella, vein-arterial extracorporeal membrane oxygenation and ventricular assist devises have been increased in use during the following years due to a reduced preload on injured myocardium during acute myocardial infarction, thus significantly averting the complication of cardiogenic shock. But, despite current therapies acute myocardial infarction-related cardiogenic shock remain as one of the most common reasons of high 30-day mortality. This article summarizes the importance of early diagnosis and timely intervention of acute myocardial infarction and cardiogenic shock patients.

  • Open Access

    Use of indicators of systolic and diastolic functions of the left ventricle in the diagnosis of early cardiotoxicity during chemotherapy with doxorubicin: An open, prospective, nonrandomized study

    by Irina A. Karputs, Victor A. Snezhitskiy, Mikhail N. Kurbat, Volga A. Harustovich, Yulia I. Karpovich, Alexander Y. Rubinskij, Tatiana A. Smirnova, Andrei S. Babenka, Снежицкий Виктор Александрович, Горустович Ольга Анатольевна, et al.

    BACKGROUND: The search for new markers of early cardiotoxicity (CT) may help reduce the incidence of severe complications in the cardiovascular system during chemotherapy with doxorubicin. AIM: To determine echocardiography (EchoCG) parameters with the potential as CT markers in patients with primary breast cancer (BC) 12 months after the end of chemotherapy with doxorubicin. MATERIAL AND METHODS: An open, prospective, nonrandomized study included 100 patients with verified BC who were treated at the Grodno University Clinic (Grodno, Belarus). Twelve months after the end of chemotherapy, 10 patients were excluded from the general group (7 women refused inclusion, the global longitudinal deformation of the myocardium could not be measured in 3 because of a poor acoustic window). All patients underwent transthoracic echocardiography with the assessment of systolic and diastolic myocardial function before and 12 months after the end of chemotherapy. RESULTS: In 24/90 (26.6%) patients, a relative (before / after 12 months) decrease in global longitudinal myocardial deformity 12% (cardiotoxicity manifestation, CT+ subgroup) was detected. The cutoff point of the absolute decrease in global longitudinal myocardial deformation after 12 months was 18.0% (sensitivity, 87.9%; specificity, 83.7%). Significant differences were found between the absolute values of echocardiography in the CT+ and CT− (without CT manifestations) subgroups 12 months after the end of chemotherapy: the indexed final diastolic volume (FDV) was in 54 (49; 61) CT+ and 61 (53; 65) in CT− (p=0.034), the indexed final systolic volume (FSV) was 17 (15; 20) in CT+ and 20 (17; 23) in CT− (p=0.031), and the ratio of the rates of peaks of early and late filling of the left ventricle (E/A) in was 1.13 (1.10; 1.27) in CT+ and 1.29 (1.15; 1.45) in CT− (p=0.031). The specificity, sensitivity, and cutoff points for these parameters were established. The cutoff, sensitivity, and specificity were 57.7 62.1%, and 66.7% for FDV; 18.8, 60.6%, and 62.5% for FSV; and 1.18, 68.2%, and 66.7% for E/A, respectively. CONCLUSION: The E/A, FDV, and FSV are candidate markers of CT 12 months after the end of chemotherapy with doxorubicin in patients with BC.

  • Open Access

    Non-Invasive Electrophysiological Markers Associated With Long QT Syndrome

    by Andrey V. Ardashev, Victor A. Snezhitskiy, Liudmila V. Kalatsei, Снежицкий Виктор Александрович, Колоцей Людмила Владимировна

    Long QT syndrome (LQTS) is a life-threatening channelopathy, characterized by permanent or transient QT interval prolongation on the 12-lead electrocardiogram and syncope associated with malignant ventricular rhythm disturbances, particularly polymorphic ventricular tachycardia also known as torsade de pointes. Corrected QT (QTc) interval measurement remains the initial source of LQTS diagnosis in any patient, but the borderline QTc interval prolongation should induce further investigation. Genetic testing has the greatest value to provide definitive diagnosis in such situations, but it cant be applied to each patient routinely, putting aside that it can often be incomprehensive, costly or unavailable. The present review discusses the most promising non-invasive electrophysiological markers associated with Long QT syndrome, particularly in absence of visible QT interval prolongation and clinical manifestations.


  • Open Access

    CLINICAL CASE OF COMBINATION OF NON-COMPACT MYOCARDIUM OF THE LEFT VENTRICLE WITH CONGENITAL ANOMALY OF THE CORONARY ARTERIES

    by Т. Л. Кепурко (T. L. Kepurko), Educational Institution “Grodno State Medical University”, В. А. Снежицкий (V. A. Snezhitskiy), С. Н. Литвинович (S. N. Litvinovich), А. Ю. Рубинский (A. Yu. Rubinskij), Г. А. Мадекина (G. A. Madekina), Е. Н. Черная (E. N. Chernaya), Ж. Г. Епифанова (Zh. G. Epifanova), Grodno Regional Clinical Cardiological Center

    КЛИНИЧЕСКИЙ СЛУЧАЙ СОЧЕТАНИЯ НЕКОМПАКТНОГО МИОКАРДА ЛЕВОГО ЖЕЛУДОЧКА С ВРОЖДЕННОЙ АНОМАЛИЕЙ КОРОНАРНЫХ АРТЕРИЙ

  • Open Access

    METHODOLOGICAL APPROACHES TO MEASURING AND ESTIMATING THE DURATION OF QT INTERVAL OF A STANDARD ELECTROCARDIOGRAM

    by Л. В. Колоцей (L. V. Kalatsei), Educational Institution “Grodno State Medical University”, В. А. Снежицкий (V. A. Snezhitskiy)

    Интерпретация каждой электрокардиограммы должна включать измерение и оценку интервала QT, как увеличение, так и уменьшение продолжительности которого ассоциировано с риском возникновения жизнеугрожающих желудочковых аритмий и внезапной сердечной смерти. В настоящей статье отражены методологические подходы к определению, измерению и оценке длительности интервала QT, рассмотрен характер его зависимости от пола, возраста и частоты сердечных сокращений у пациента, а также описан ряд показателей, вычисляемых на его основе. На основании проведенного анализа литературы сформулированы рекомендации по измерению и оценке интервала QT стандартной электрокардиограммы.


  • Open Access

    LONG QT SYNDROME. PART 2

    by Educational Institution «Grodno State Medical University», Л. В. Колоцей (L. V. Kalatsei), В. А. Снежицкий (V. A. Snezhitskiy)

    СИНДРОМ УДЛИНЕННОГО ИНТЕРВАЛА QT. ЧАСТЬ 2


  • Open Access

    GRODNO STATE MEDICAL UNIVERSITY CELEBRATES ITS 60TH ANNIVERSARY

    by В. А. Снежицкий (V. A. Snezhitskiy), Educational Institution “Grodno State Medical University”, В. В. Воробьев (V. V. Vorobiev), С. Б. Вольф (S. B. Volf), V. I. Shyshko

    Юбилейные даты – важное событие в деятельности университета. За 60 лет своей истории Гродненский государственный медицинский университет стал крупным учебным, научным и клиническим центром в системе образования и здравоохранения Республики Беларусь. В статье приведены сведения о современном состоянии университета, его основных достижениях, ученых и сотрудниках, внесших значительный вклад в становление и развитие университета.